The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Home | ERBP

ERBP


10 / 18 results found

{%SMALL_TITLE%}
{%SUMMARY_INFO%}

{%BOTTOM_TEXT%}

{%SMALL_TITLE%}

{%EXCERPT%}

{%BOTTOM_TEXT%}

Click here to register now!

Speaker
Charles Ferro, United Kingdom

Panellists
Mehmet Kanbay, Türkiye
Valerie Luyckx, Switzerland

Moderator
Pantelis Sarafidis, Greece

Thursday, November 14, 2024, at 5:00 PM (CET)

ERBP